Prostate Cancer — Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
Citation(s)
BMS CA180-097: A Phase II Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer, Previously Treated With Chemotherapy